GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Optomed PLC (OHEL:OPTOMED) » Definitions » Total Liabilities

Optomed (OHEL:OPTOMED) Total Liabilities : €8.14 Mil (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Optomed Total Liabilities?

Optomed's Total Liabilities for the quarter that ended in Dec. 2024 was €8.14 Mil.

Optomed's quarterly Total Liabilities declined from Jun. 2024 (€8.34 Mil) to Sep. 2024 (€7.57 Mil) but then increased from Sep. 2024 (€7.57 Mil) to Dec. 2024 (€8.14 Mil).

Optomed's annual Total Liabilities declined from Dec. 2022 (€10.96 Mil) to Dec. 2023 (€8.72 Mil) and declined from Dec. 2023 (€8.72 Mil) to Dec. 2024 (€8.14 Mil).


Optomed Total Liabilities Historical Data

The historical data trend for Optomed's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Optomed Total Liabilities Chart

Optomed Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.00 11.95 10.96 8.72 8.14

Optomed Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.72 8.45 8.34 7.57 8.14

Optomed Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Optomed's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=5.583+(2.328+0.233
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=8.14

Total Liabilities=Total Assets (A: Dec. 2024 )-Total Equity (A: Dec. 2024 )
=31.781-23.637
=8.14

Optomed's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=5.583+(2.328+0.233
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=8.14

Total Liabilities=Total Assets (Q: Dec. 2024 )-Total Equity (Q: Dec. 2024 )
=31.781-23.637
=8.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Optomed Total Liabilities Related Terms

Thank you for viewing the detailed overview of Optomed's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Optomed Business Description

Traded in Other Exchanges
Address
Yrttipellontie 1, Oulu, FIN, 90230
Optomed PLC is a Finnish medical technology company and a manufacturer of handheld fundus cameras and screening software. The company operates in two business segments which are Devices and Software. Devices segment develops, commercializes, and manufactures easy-to-use and affordable handheld fundus cameras, that are suitable for any clinic for screening of various eye diseases, such as diabetic retinopathy, glaucoma, and AMD. The Software segment develops and commercializes screening software for diabetic retinopathy and cancer screening for healthcare organizations. The company operates in Finland, China, and other countries.

Optomed Headlines

No Headlines